Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
BASKING RIDGE, N.J., April 10, 2017 -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline focused on immune modulation, announces today that the Company’s 2017 annual stockholder meeting will be held on Tuesday, May 16, 2017 at 11:00 a.m., Eastern Daylight Savings Time, at Hotel Indigo Basking Ridge, 80 Allen Road, Basking Ridge, NJ 07920.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company is investigating its lead product candidate, CLBS03, for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. The Company’s subsidiary, PCT, is a well-known development and manufacturing partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. For more information on Caladrius please visit www.caladrius.com.
Contacts: Investors: LHA Anne Marie Fields Senior Vice President Phone: +1-212-838-3777 Email: [email protected] Media: Caladrius Biosciences, Inc. Eric Powers Director, Communications and Marketing Phone: +1-212-584-4173 Email: [email protected]
